北海康(kang)成制藥(yao)有限公(gong)司已任命胡正國(guo)(guo)先生為非(fei)執(zhi)(zhi)行(xing)董(dong)(dong)(dong)(dong)事(shi)(shi)(shi)，接替離任北海康(kang)成董(dong)(dong)(dong)(dong)事(shi)(shi)(shi)會(hui)的樂(le)霄先生。在出任藥(yao)明(ming)康(kang)德副董(dong)(dong)(dong)(dong)事(shi)(shi)(shi)長、全球(qiu)首(shou)(shou)席投資官(guan)(guan)、執(zhi)(zhi)行(xing)董(dong)(dong)(dong)(dong)事(shi)(shi)(shi)、戰略(lve)委員會(hui)成員之前(qian)，胡正國(guo)(guo)曾(ceng)擔(dan)任該(gai)公(gong)司聯席首(shou)(shou)席執(zhi)(zhi)行(xing)官(guan)(guan)、首(shou)(shou)席財務(wu)(wu)官(guan)(guan)和首(shou)(shou)席營(ying)運營(ying)官(guan)(guan)。加入藥(yao)明(ming)康(kang)德之前(qian)，胡正國(guo)(guo)曾(ceng)任多個(ge)高級管理(li)層職務(wu)(wu)，包(bao)括Tanox Inc.高級副總(zong)裁兼首(shou)(shou)席運營(ying)官(guan)(guan)，渤健業務(wu)(wu)計劃經理(li)，在此(ci)之前(qian)，擔(dan)任默克高級財務(wu)(wu)分析師(shi)。胡先生現任基石藥(yao)業非(fei)執(zhi)(zhi)行(xing)董(dong)(dong)(dong)(dong)事(shi)(shi)(shi)。他(ta)曾(ceng)任藥(yao)明(ming)生物技術有限公(gong)司非(fei)執(zhi)(zhi)行(xing)董(dong)(dong)(dong)(dong)事(shi)(shi)(shi)，以及(ji)Viela Bio Inc.董(dong)(dong)(dong)(dong)事(shi)(shi)(shi)。(醫(yi)藥(yao)健聞)